Track topics on Twitter Track topics that are important to you
Acorda Therapeutics, Inc. was established in March 1995 to develop therapeutic products for spinal cord injury ("SCI") and other central nervous system disorders. Acorda is focusing its initial development efforts on a range of therapeutics for individuals with chronic, or long term, SCI. Currently, there is no therapy that improves neurological function in chronic SCI patients.
However, Acorda's clinical stage product, Fampridine-SR, has improved neurological function for patients with chronic SCI in Phase 2 clinical trials. The Company believes that the therapeutic products it develops for SCI are likely also to have applications in other neurological conditions-for example, both Fampridine-SR and the Company's M1 monoclonal antibody ("M1") product have shown promise as therapies for multiple sclerosis ("MS"). Other potential markets for the Company's products include traumatic brain injury, Parkinson's disease and stroke.
15 Skyline Drive
United States of America
The heat is on Acorda Therapeutics once again. Months after Acorda lost a key group of patents, the FDA has declined to review, at least for now, an experimental Parkinson’s disease drug that is cri...
More than 24% was taken off the market value of neurological disorders specialist Acorda Therapeutics…
Acorda Therapeutics will submit to the FDA its new-drug application for Inbrija by the end of this quarter. -More-
The US FDA has refused to let Acorda Therapeutics Inc. file Inbrija, its inhalable version of levodopa, for review.
Acorda Therapeutics was turned away at the FDA’s doorstep when it tried to submit a marketing application for a new drug to treat Parkinson’s disease.
ARDSLEY, N.Y.--(BUSINESS WIRE) June 29, 2017 -- Acorda Therapeutics, Inc. (NASDAQ: ACOR) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Inbrija (CVT-301,...
Acorda Therapeutics said today it will work to address FDA concerns that prompted the agency to send a “Refuse to File” (RTF) letter in response to the company’s New Drug Application (NDA) for P...
Aimed at fending off a potential hostile bid for the company, Acorda Therapeutics adopts a poison pill provision effective today declaring a dividend distribution of one preferred share purchase right...
ALDEX GS™ Tablets
ALDEX GS DMTablets
The purpose of this study is to evaluate the long-term safety, tolerability and activity of Fampridine-SR in subjects with multiple sclerosis who have previously participated in either an ...
The purpose of this study is to evaluate the safety, tolerability and activity of Fampridine-SR when administered for up to 36 additional months in subjects who previously participated in ...
The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...
Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System
The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...
Acorda Therapeutics, Inc. was established in March 1995 to develop therapeutic products for spinal cord injury ("SCI") and other central nervous system disorders. Acorda is focusing its initial develo...
Acorda Therapeutics is a biotechnology company developing therapies for multiple sclerosis, spinal cord injury and other nervous system disorders. The Company's marketed products ...
Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...
Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...
Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...
We have published hundreds of Acorda Therapeutics news stories on BioPortfolio along with dozens of Acorda Therapeutics Clinical Trials and PubMed Articles about Acorda Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Acorda Therapeutics Companies in our database. You can also find out about relevant Acorda Therapeutics Drugs and Medications on this site too.
Spinal Cord Disorders
The spinal cord is a bundle of nerves that runs down the middle of the back which carry signals back and forth between the body and brain. It is protected by vertebrae, which are the bone disks that make up the spine. An accident that damages the verte...
Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...
Anxiety is caused by stress. It is a natural reaction, and is beneficial in helping us deal with tense situations and pressure. It is deterimental when is becomes an excessive, irrational dread of everyday situations. The most common types of anxiety di...